Previsioni di mercato degli adiuvanti per vaccini in Europa fino al 2030 – Analisi regionale – per classe di adiuvanti (adiuvante di sale minerale, adiuvante di emulsione, adiuvante di liposomi e altri) e tipo (adiuvante di vaccino umano e adiuvante di vaccino veterinario)
Le approvazioni degli adiuvanti per vaccini veterinari guidano il mercato europeo degli adiuvanti per vaccini
La vaccinazione degli animali contro le malattie comuni rimane il metodo più efficace al mondo per prevenire perdite finanziarie e di altro tipo dovute a malattie infettive nell\'allevamento animale. Le approvazioni normative per gli adiuvanti per vaccini veterinari sono in aumento, con la crescente attenzione dei produttori allo sviluppo di vaccini con maggiore efficacia e stabilità. Montanide è uno degli adiuvanti per vaccini veterinari noti. La gamma di adiuvanti Montanide si basa su tre tecnologie principali: emulsioni, microemulsioni e polimeri. Pertanto, un aumento delle approvazioni degli adiuvanti per vaccini veterinari accelera la crescita complessiva del mercato degli adiuvanti per vaccini.
Panoramica del mercato degli adiuvanti per vaccini in Europa
Il mercato degli adiuvanti per vaccini in Europa è stato segmentato in Germania, Regno Unito, Francia, Italia, Spagna e resto d\'Europa. Alcuni dei principali produttori di vaccini sono presenti in Germania. A dicembre 2022, Evonik ha lanciato uno squalene di origine vegetale denominato PhytoSquene per migliorare l\'efficacia del vaccino. È un derivato non animale adatto per vaccini e altre applicazioni farmaceutiche. PhytoSquene è il primo squalene derivato dall\'olio di amaranto noto introdotto sul mercato per gli adiuvanti nei farmaci indicati per uso parenterale. Questa ultima innovazione di Evonik è pensata per fornire al mercato soluzioni sostenibili e non derivate da animali. Nel 2021, Evonik ha lanciato il colesterolo di grado farmaceutico e di origine vegetale \"PhytoChol\".
Ricavi e previsioni del mercato degli adiuvanti per vaccini in Europa fino al 2030 (milioni di $ USA)
Segmentazione del mercato degli adiuvanti per vaccini in Europa
Il mercato degli adiuvanti per vaccini in Europa è suddiviso in classe, tipo e paese.
In base alla classe, il mercato degli adiuvanti per vaccini in Europa è suddiviso in adiuvante di sali minerali, adiuvante di emulsione, adiuvante di liposomi e altri. Il segmento degli adiuvanti di sali minerali ha detenuto la quota maggiore del mercato degli adiuvanti per vaccini in Europa nel 2022.
In base al tipo, il mercato degli adiuvanti per vaccini in Europa è suddiviso in adiuvante per vaccini umani e adiuvante per vaccini veterinari. Il segmento degli adiuvanti per vaccini umani ha detenuto una quota maggiore del mercato degli adiuvanti per vaccini in Europa nel 2022.
In base al paese, il mercato europeo degli adiuvanti per vaccini è segmentato in Germania, Regno Unito, Francia, Italia, Spagna e resto d\'Europa. La Germania ha dominato la quota di mercato degli adiuvanti per vaccini in Europa nel 2022.
Croda International Plc; CSL Ltd; Dynavax Technologies Corp; GSK Plc; InvivoGen SAS; Novavax Inc.; Phibro Animal Health Corp; Seppic SA; e SPI Pharma Inc sono alcune delle aziende leader che operano nel mercato europeo degli adiuvanti per vaccini.
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Vaccine Adjuvants Market – Key Market Dynamics
4.1 Europe Vaccine Adjuvants Market – Key Market Dynamics
4.2 Market Drivers
4.2.1 Rising Number of Infectious Disease Outbreaks and Pandemic
4.2.2 Approvals of Veterinary Vaccine Adjuvants
4.3 Market Restraints
4.3.1 Product Recalls and Adverse Effects
4.4 Market Opportunities
4.4.1 Advancements in Biotechnology and Immunology
4.5 Future Trends
4.5.1 Technological Advancements
4.6 Impact of Drivers and Restraints:
5. Vaccine Adjuvants Market –Europe Market Analysis
5.1 Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
5.2 Europe Vaccine Adjuvants Market Forecast and Analysis
6. Europe Vaccine Adjuvants Market Analysis – by Adjuvant Class
6.1 Overview
6.2 Mineral Salt Adjuvant
6.2.1 Overview
6.2.2 Mineral Salt Adjuvant: Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
6.3 Emulsion Adjuvant
6.3.1 Overview
6.3.2 Emulsion Adjuvant: Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
6.4 Liposome Adjuvant
6.4.1 Overview
6.4.2 Liposome Adjuvant: Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
6.5 Others
6.5.1 Overview
6.5.2 Others: Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
7. Europe Vaccine Adjuvants Market Analysis – by Type
7.1 Human Vaccine Adjuvant
7.1.1 Overview
7.1.2 Human Vaccine Adjuvant: Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
7.2 Veterinary Vaccine Adjuvant
7.2.1 Overview
7.2.2 Veterinary Vaccine Adjuvant: Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8. Europe Vaccine Adjuvants Market –Country Analysis
8.1 Europe
8.1.1 Europe Vaccine Adjuvants Market
8.1.1.1 Germany: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.1.1 Overview
8.1.1.1.2 Germany: Glucose Monitoring Devices Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.1.3 Germany: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
8.1.1.1.4 Germany: Vaccine Adjuvants Market Breakdown, by Type
8.1.1.2 United Kingdom: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.2.1 Overview
8.1.1.2.2 United Kingdom: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.2.3 United Kingdom: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
8.1.1.2.4 United Kingdom: Vaccine Adjuvants Market Breakdown, by Type
8.1.1.3 France: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.3.1 Overview
8.1.1.3.2 France: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.3.3 France: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
8.1.1.3.4 France: Vaccine Adjuvants Market Breakdown, by Type
8.1.1.4 Italy: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.4.1 Overview
8.1.1.4.2 Italy: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.4.3 Italy: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
8.1.1.4.4 Italy: Vaccine Adjuvants Market Breakdown, by Type
8.1.1.5 Spain: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.5.1 Overview
8.1.1.5.2 Spain: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.5.3 Spain: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
8.1.1.5.4 Spain: Vaccine Adjuvants Market Breakdown, by Type
8.1.1.6 Rest of Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.6.1 Overview
8.1.1.6.2 Rest of Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.6.3 Rest of Europe Vaccine Adjuvants Market Breakdown, by Adjuvant Class
8.1.1.6.4 Rest of Europe Vaccine Adjuvants Market Breakdown, by Type
9. Industry Landscape
9.1 Overview
9.2 Growth Strategies in the Global Vaccine Adjuvants Market
9.3 Organic Developments
9.3.1 Overview
9.4 Inorganic Developments
9.4.1 Overview
10. Company Profiles
10.1 SPI Pharma Inc
10.1.1 Key Facts
10.1.2 Business Description
10.1.3 Products and Services
10.1.4 Financial Overview
10.1.5 SWOT Analysis
10.1.6 Key Developments
10.2 GSK Plc
10.2.1 Key Facts
10.2.2 Business Description
10.2.3 Products and Services
10.2.4 Financial Overview
10.2.5 SWOT Analysis
10.2.6 Key Developments
10.3 CSL Ltd
10.3.1 Key Facts
10.3.2 Business Description
10.3.3 Products and Services
10.3.4 Financial Overview
10.3.5 SWOT Analysis
10.3.6 Key Developments
10.4 Seppic SA
10.4.1 Key Facts
10.4.2 Business Description
10.4.3 Products and Services
10.4.4 Financial Overview
10.4.5 SWOT Analysis
10.4.6 Key Developments
10.5 Dynavax Technologies Corp
10.5.1 Key Facts
10.5.2 Business Description
10.5.3 Products and Services
10.5.4 Financial Overview
10.5.5 SWOT Analysis
10.5.6 Key Developments
10.6 InvivoGen SAS
10.6.1 Key Facts
10.6.2 Business Description
10.6.3 Products and Services
10.6.4 Financial Overview
10.6.5 SWOT Analysis
10.6.6 Key Developments
10.7 Croda International Plc
10.7.1 Key Facts
10.7.2 Business Description
10.7.3 Products and Services
10.7.4 Financial Overview
10.7.5 SWOT Analysis
10.7.6 Key Developments
10.8 Novavax Inc
10.8.1 Key Facts
10.8.2 Business Description
10.8.3 Products and Services
10.8.4 Financial Overview
10.8.5 SWOT Analysis
10.8.6 Key Developments
10.9 Phibro Animal Health Corp
10.9.1 Key Facts
10.9.2 Business Description
10.9.3 Products and Services
10.9.4 Financial Overview
10.9.5 SWOT Analysis
10.9.6 Key Developments
11. Appendix
11.1 About The Insight Partners
List of Tables
Table 1. Europe Vaccine Adjuvants Market Segmentation
Table 2. Europe Vaccine Adjuvants Market Revenue and Forecasts To 2030 (US$ Million)
Table 3. Germany: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 4. Germany: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 5. United Kingdom: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 6. United Kingdom: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 7. France: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 8. France: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 9. Italy: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 10. Italy: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 11. Spain: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 12. Spain: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 13. Rest of Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 14. Rest of Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 15. Organic Developments Done by Companies
Table 16. Inorganic Developments Done by Companies
List of Figures
Figure 1. Europe Vaccine Adjuvants Market Segmentation, by Country
Figure 2. Impact Analysis of Drivers and Restraints
Figure 3. Europe Vaccine Adjuvants Market Revenue (US$ Million), 2022–2030
Figure 4. Europe Vaccine Adjuvants Market Share (%) – by Adjuvant Class (2022 and 2030)
Figure 5. Mineral Salt Adjuvant: Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 6. Emulsion Adjuvant: Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Liposome Adjuvant: Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Others: Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Europe Vaccine Adjuvants Market Share (%) – by Type (2022 and 2030)
Figure 10. Human Vaccine Adjuvant: Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Veterinary Vaccine Adjuvant: Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. Europe Vaccine Adjuvants Market – Revenue by Key Countries Revenue 2022 (US$ Million)
Figure 13. Europe Vaccine Adjuvants Market (2022 and 2030)
Figure 14. Germany: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 15. United Kingdom: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 16. France: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 17. Italy: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 18. Spain: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 19. Rest of Europe Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 20. Growth Strategies in the Vaccine Adjuvants Market
- SPI Pharma Inc
- GSK Plc
- CSL Ltd
- Seppic SA
- Dynavax Technologies Corp
- InvivoGen SAS
- Croda International Plc
- Novavax Inc
- Phibro Animal Health Corp
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe vaccine adjuvants market.
- Highlights key business priorities to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Europe vaccine adjuvants market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the Europe vaccine adjuvants market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.